- Home
- GTEC vs BNR Comparison
GTEC vs BNR Comparison
Compare GTEC & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTEC
- BNR
- Stock Information
- Founded
- GTEC 2006
- BNR 2014
- Country
- GTEC United States
- BNR China
- Employees
- GTEC N/A
- BNR N/A
- Industry
- GTEC Industrial Machinery/Components
- BNR Medical Specialities
- Sector
- GTEC Industrials
- BNR Health Care
- Exchange
- GTEC Nasdaq
- BNR Nasdaq
- Market Cap
- GTEC 35.8M
- BNR 29.1M
- IPO Year
- GTEC N/A
- BNR 2020
- Fundamental
- Price
- GTEC $1.98
- BNR $4.22
- Analyst Decision
- GTEC
- BNR
- Analyst Count
- GTEC 0
- BNR 0
- Target Price
- GTEC N/A
- BNR N/A
- AVG Volume (30 Days)
- GTEC 123.9K
- BNR 29.7K
- Earning Date
- GTEC 08-14-2025
- BNR 08-21-2025
- Dividend Yield
- GTEC N/A
- BNR N/A
- EPS Growth
- GTEC N/A
- BNR N/A
- EPS
- GTEC 1.14
- BNR N/A
- Revenue
- GTEC $82,898,634.00
- BNR $72,112,038.00
- Revenue This Year
- GTEC $3.28
- BNR $136.32
- Revenue Next Year
- GTEC N/A
- BNR N/A
- P/E Ratio
- GTEC $1.75
- BNR N/A
- Revenue Growth
- GTEC N/A
- BNR 0.53
- 52 Week Low
- GTEC $1.17
- BNR $2.18
- 52 Week High
- GTEC $2.94
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- GTEC 46.91
- BNR 63.77
- Support Level
- GTEC $1.95
- BNR $3.06
- Resistance Level
- GTEC $2.09
- BNR $3.50
- Average True Range (ATR)
- GTEC 0.11
- BNR 0.21
- MACD
- GTEC -0.01
- BNR 0.05
- Stochastic Oscillator
- GTEC 28.72
- BNR 95.65
About GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.